RESUMEN
This article provides a primer on medical device regulations in the United States, Europe, and Canada. Software tools are being developed and shared globally to enhance the accessibility and usefulness of genomic databases. Interactive software tools, such as email or mobile alert systems providing variant classification updates, are opportunities to democratize access to genomic data beyond laboratories and clinicians. Uncertainty over the reliability of outputs, however, raises concerns about potential harms to patients, especially where software is accessible to lay users. Developers may also need to contend with unfamiliar medical device regulations. The application of regulatory controls to genomic software could improve patient and user safety, but could also stifle innovation. Legal uncertainty for developers is compounded where software applications are made available globally (implicating multiple regulatory frameworks), and directly to lay users. Moreover, there is considerable uncertainty over the application of (evolving) medical device regulations in the context of both software and genetics. In this article, criteria and examples are provided to inform determinations of software as medical devices, as well as risk classification. We conclude with strategies for using genomic communication and interpretation software to maximize the availability and usefulness of genetic information, while mitigating the risk of harm to users.
Asunto(s)
Programas Informáticos , Bases de Datos Genéticas , Genética , Genómica/métodos , Humanos , Estados UnidosRESUMEN
Stem cells may not systematically obey traditional Phase I-IV clinical translation models. In response, various actors have suggested that stem cell-based medical innovation models could catalyze translation instead. Accordingly, calls were made to adopt more permissive approaches to stem cell translation. Yet, the Phase I-IV paradigm remains the standard within the scientific community. This article seeks to advance the stalemated discussions by proposing an alternative model for consideration. In it, we argue that a stem cell-based learning health system may be able to reconcile these two models. Centered on the acceleration of evidence and knowledge flow, a stem cell-based learning health system could maximize patient retention and data follow-up, thereby promoting inclusive system learning and improvement.
Asunto(s)
Medicina Regenerativa/tendencias , Investigación con Células Madre , Investigación Biomédica Traslacional , Trasplante de Médula Ósea , Tratamiento Basado en Trasplante de Células y Tejidos/tendencias , Ensayos Clínicos como Asunto , Toma de Decisiones , Turismo Médico , Medicina Regenerativa/métodos , Terapias en InvestigaciónRESUMEN
Recent gene editing experiments carried out in human embryos have raised the question of whether interventions like the introduction of a CCR5-Δ32 deletion, which could provide heritable resistance to HIV infection, ought to be considered enhancements. Many authors have used the term "enhancement" in different ways, some based on patients' biomedical outcomes and others on their social context. These classifications are often considered overly imprecise. Nevertheless, the concept of "enhancement" could affect the ways in which these applications are regulated in different jurisdictions, the availability of coverage by insurers or public health care, and the force of public opinion in shaping future policy on gene editing. In order to ethically situate resistance to communicable disease with reference to other techniques, this article provides an overview of its similarities and differences with disease gene therapy in embryos, gene therapy in consenting adults, and vaccination. In discussing key ethical features of CCR5-Δ32 deletion (including its frequency in various populations, biological mechanism, benefits for individuals, and use in previous clinical trials) we offer some potential guideposts for the continuing discussion on how to classify "enhancements" in the age of CRISPR gene editing.